NLTX Projected Dividend Yield
Neurogene Inc ( NASDAQ : NLTX )Neoleukin Therapeutics is a biopharmaceutical company, focused on immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Co. is focused on key cytokine mimetics, which Co. refers to as Neoleukin de novo cytokine mimetics, that can be modified to adjust affinity, thermodynamic stability, resistance to biochemical modification, pharmacokinetic characteristics, potency and targeting to tumor or inflamed tissues. Co.'s NL-201 is designed to mimic the therapeutic activity of the cytokines interleukin-2 and interleukin-15 for the potential treatment of various types of cancer, including renal cell carcinoma, melanoma, and hematological malignancies. 20 YEAR PERFORMANCE RESULTS |
NLTX Dividend History Detail NLTX Dividend News NLTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |